INO80

Chromatin-remodeling ATPase INO80 · Q9ULG1 · INO80 on Sugi Atlas →

0 patent compounds predicted against INO80, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to INO80 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS PHASE2COMPLETED
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma PHASE2COMPLETED
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer PHASE2UNKNOWN
Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma PHASE2RECRUITING
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells. nanUNKNOWN
Target of Suv420h1/2 in Hepatocytes nanRECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Proteomic-Based Profiling of Lymphomas: Chromatin Proteomics; Composition and Modification of Histone and Non-Histone Chromosomal Proteins nanCOMPLETED
Efficacy Study of a Food Supplement With Myo-inositol, N-Acetyl-Cystein, Zinc and Vitamins on Sperm DNA Fragmentation nanRECRUITING
Precision High-Intensity Training Through Epigenetics (PHITE) nanCOMPLETED
Chi-GVM Regimen for the Treatment of R/R PTCL nanUNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED
Hippotherapy in Children With Spinal Muscular Atrophy nanRECRUITING
Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System nanCOMPLETED
Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic Evolution of Molecular Subtypes in Extensive-Stage Small Cell Lung Cancer During First-Line Chemoimmunotherapy nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a INO80 binder may also engage these)

ProteinNameSimilarity
Q6ZPV2 1.000 Q6ZPV2 →
Q8RXS6 1.000 Q8RXS6 →
O13682 0.997 O13682 →
Q27571 0.996 Q27571 →
B9EJV3 0.996 B9EJV3 →
Q9SB51 0.995 Q9SB51 →
MAP3K13 Mitogen-activated protein kinase kinase kinase 13 0.995 landscape →
P58270 0.995 P58270 →
P46200 0.995 P46200 →
Q6CIT4 0.995 Q6CIT4 →
Q6CJ38 0.995 Q6CJ38 →
F4J9M5 0.995 F4J9M5 →
Q6EEF3 0.995 Q6EEF3 →
Q9D4V4 0.995 Q9D4V4 →
F4J6F6 0.994 F4J6F6 →
Q11107 0.994 Q11107 →
Q6FK48 0.994 Q6FK48 →
Q9VDY1 0.994 Q9VDY1 →
Q90ZS6 0.994 Q90ZS6 →
A7MBB4 0.994 A7MBB4 →
A6QQR4 0.994 A6QQR4 →
P38827 0.994 P38827 →
Q811D2 0.994 Q811D2 →
A2A3K4 0.993 A2A3K4 →
O61608 0.993 O61608 →
Q23238 0.993 Q23238 →
Q9SR66 0.993 Q9SR66 →
Q63553 0.993 Q63553 →
Q5R978 0.993 Q5R978 →
Q7T2A3 0.993 Q7T2A3 →